HIV resistance to lenacapavir weakens the virus's ability to replicate

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
BlackDoctor.org

HIV Prevention Works — So Why Are Black Communities Still at Risk?

PrEP is one of the most powerful tools in HIV prevention. Yet for many Black LGBTQ+ people, getting access to the medication is far harder than it should be.
C&EN

HIV can develop resistance to lenacapavir, but at a cost to the virus

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
Fierce Biotech

Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

The near death — and last-minute reprieve — of a trial for an HIV vaccine

A trial was about to launch for a vaccine that would ward off the HIV virus. It would be an incredible breakthrough. Then it ...

Double threat: HIV and hepatitis B co-infection increases risk of kidney dysfunction

A new 10-year regional study reveals that adults living with both HIV and hepatitis B virus across the Asia-Pacific face ...

Letting 10K+ Floridians go without HIV drug access is reckless, especially in Miami | Opinion

What are lawmakers doing about this during the 2026 legislative session?